Answers are grounded in this paper and cite their sources.
Introduction Rho kinase (ROCK) inhibitors (RKIs) have been available commercially as topical ocular hypotensive agents for approximately a decade. RKIs have promise as their presumed mechanism of action is increased trabecular meshwork (TM) outflow, the presumed primary site of pathology in open-angle glaucoma.
No takes yet. Share an insight, caveat, or question.
Javitt et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: